Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05148039
Other study ID # 306930
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 7, 2022
Est. completion date July 3, 2023

Study information

Verified date August 2023
Source Queen Mary University of London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study involves a comprehensive nutritional assessment of hEDS participants who have functional gastrointestinal disorders and dietary intervention to broaden their food choices and nutritional intake.


Description:

The impact of diet on symptoms in patients with Hypermobile Ehlers Danlos Syndrome (hEDS/HSD) is widely recognised yet poorly understood. The investigators aim is to assess existing dietary patterns and nutritional status in hEDS/HSD as well as pilot a personalised dietary strategy to optimise nutrition. Participants recruited from EDS UK and a tertiary Neurogastroenterology clinic at the Royal London Hospital will undergo comprehensive nutritional assessment and blood tests. The investigators will then undertake a feasibility study of personalised dietary intervention in select cohort of patients.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date July 3, 2023
Est. primary completion date July 3, 2023
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - Have completed Phase I of the CANDI-hEDS study - Diagnosis of hEDS / HSD according to physical examination and history taking - Diagnosis of Functional Dyspepsia and / or Irritable Bowel Syndrome according to Rome IV criteria - Able and willing to give informed consent - Access to video conferencing and a smart phone device - Able to travel to the Wingate Institute Exclusion Criteria: - Dependent upon artificial feeding (parenteral and enteral) - Structural gastrointestinal disease - Any chronic health condition which already requires a restricted diet e.g. diabetes mellitus - Functional vomiting disorder with associated weight loss - Multiple Type I hypersensitivity reactions to food groups (i.e. anaphylaxis, urticaria, respiratory symptoms or positive RAST tests). - Previous or current severe mental health disorder (e.g. severe depression with suicidal ideation) - Previous or current eating disorder - Positive screen for avoidant restrictive food intake disorder (ARFID)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Dietician advice
Personalised dietetic advice

Locations

Country Name City State
United Kingdom Queen Marys University London London

Sponsors (2)

Lead Sponsor Collaborator
Queen Mary University of London University College, London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients Number of patients who adhere to dietary recommendations based on acceptability of intervention and ease of delivery. 3 months
Secondary United Kingdom Diet Quality Index as calculated by the Scottish Collaborative Group Food Frequency Questionnaire (SCG FFQ) 170- item semi-quantitative questionnaire, designed to assess the habitual diet of medium to large sized populations during the previous 3 months (higher score means better diet quality) 3 months
Secondary Gastrointestinal Symptom Rating Scale (GSRS) 13-item questionnaire assessing gastrointestinal symptoms across five domains (pain, bloating, constipation, diarrhoea and satiety) over a period of one week. (min:0 max: 7, higher score means worse symptoms) 3 months
Secondary Hospital Anxiety and Depression Scale (HADS) 14-item scale assessing symptoms of either anxiety or depression (min: 0 max: 21, higher score means worse anxiety or depression) 3 months
Secondary Visceral Sensitivity Index (VSI) 15-item measurement of gastrointestinal-specific anxiety (min: 0 max: 75, higher score means worse gastrointestinal specific anxiety) 3 months
Secondary Patient Health Questionnaire-15 (PHQ-15) 15-item questionnaire to assess the domain of somatic symptoms (min: 0 max: 30, higher score means worse somatic symptoms) 3 months
Secondary Composite Autonomic Symptom Score (COMPASS-31) 31-item score to assess for symptoms of autonomic nervous system disturbance (min: 0 max 100, higher score means worse autonomic symptoms) 3 months
Secondary Short Form 6D version 2 (SF-6Dv2) 6-item questionnaire to assess impact of physical symptoms on daily functioning and quality of life (ranges from 1 (full health) to -0.574 (worst health); 0 (death)) 3 months
Secondary Resource Use Questionnaire 16-item questionnaire to assess healthcare and health product utilisation over the preceding 3 months (no minimum / maximum, no score) 3 months
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A